These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 34368991)

  • 1. Severe Dyskinesia After Administration of SARS-CoV2 mRNA Vaccine in Parkinson's Disease.
    Erro R; Buonomo AR; Barone P; Pellecchia MT
    Mov Disord; 2021 Oct; 36(10):2219. PubMed ID: 34368991
    [No Abstract]   [Full Text] [Related]  

  • 2. Does Late Levodopa Administration Delay the Development of Dyskinesia in Patients with De Novo Parkinson's Disease?
    Chung SJ; Yoo HS; Lee HS; Jeong HE; Kim SJ; Oh JS; Kim JS; Sohn YH; Lee PH
    CNS Drugs; 2018 Oct; 32(10):971-979. PubMed ID: 30027399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White matter alterations in Parkinson's disease with levodopa-induced dyskinesia.
    Ogawa T; Hatano T; Kamagata K; Andica C; Takeshige-Amano H; Uchida W; Saito Y; Shimo Y; Oyama G; Umemura A; Iwamuro H; Ito M; Hori M; Aoki S; Hattori N
    Parkinsonism Relat Disord; 2021 Sep; 90():8-14. PubMed ID: 34325387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
    Rieck M; Schumacher-Schuh AF; Altmann V; Francisconi CL; Fagundes PT; Monte TL; Callegari-Jacques SM; Rieder CR; Hutz MH
    Pharmacogenomics; 2012 Nov; 13(15):1701-10. PubMed ID: 23171335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?
    Rieck M; Schumacher-Schuh AF; Callegari-Jacques SM; Altmann V; Schneider Medeiros M; Rieder CR; Hutz MH
    Pharmacogenomics; 2015; 16(6):573-82. PubMed ID: 25872644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease.
    Silverdale MA; Nicholson SL; Crossman AR; Brotchie JM
    Mov Disord; 2005 Apr; 20(4):403-409. PubMed ID: 15593312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'COVID arm' - histological features of a delayed-type hypersensitivity reaction to Moderna mRNA-1273 SARS-CoV2 vaccine.
    Kempf W; Kettelhack N; Kind F; Courvoisier S; Galambos J; Pfaltz K
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e730-e732. PubMed ID: 34242422
    [No Abstract]   [Full Text] [Related]  

  • 9. Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients.
    Antonini A; Fung VS; Boyd JT; Slevin JT; Hall C; Chatamra K; Eaton S; Benesh JA
    Mov Disord; 2016 Apr; 31(4):530-7. PubMed ID: 26817533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Tison F; Keywood C; Wakefield M; Durif F; Corvol JC; Eggert K; Lew M; Isaacson S; Bezard E; Poli SM; Goetz CG; Trenkwalder C; Rascol O
    Mov Disord; 2016 Sep; 31(9):1373-80. PubMed ID: 27214664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis.
    Falla M; Di Fonzo A; Hicks AA; Pramstaller PP; Fabbrini G
    Parkinsonism Relat Disord; 2021 Mar; 84():52-60. PubMed ID: 33561612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Burn DJ; Kass-Iliyya L; Kellett MW; Crossman AR; Silverdale MA
    Parkinsonism Relat Disord; 2014 Apr; 20(4):452-5. PubMed ID: 24521874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease.
    Henry B; Duty S; Fox SH; Crossman AR; Brotchie JM
    Exp Neurol; 2003 Oct; 183(2):458-68. PubMed ID: 14552886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?
    Chaudhuri KR; Jenner P; Antonini A
    Mov Disord; 2019 Jun; 34(6):816-819. PubMed ID: 30983023
    [No Abstract]   [Full Text] [Related]  

  • 17. Rhabdomyolysis induced by severe levodopa induced dyskinesia in a patient with Parkinson's disease.
    Lyoo CH; Lee MS
    J Neurol; 2011 Oct; 258(10):1893-4. PubMed ID: 21499722
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of Parkinson's Disease Patients Affected by COVID-19.
    Antonini A; Leta V; Teo J; Chaudhuri KR
    Mov Disord; 2020 Jun; 35(6):905-908. PubMed ID: 32347572
    [No Abstract]   [Full Text] [Related]  

  • 19. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.